Evidence map›Paper›PMID 40034406›Full record

ArticleDrug design, development and therapy2025

Design, Synthesis and Evaluation of Novel Cyclopropanesulfonamide Derivatives for the Treatment of EGFR

Mengxuan Wang, Zhenhong Xia, Wenyan Nie, Chunlong Wang, Haoran Nie, Shuai Zhang, Jiaqi Qiu, Yang Yang, Cuifang Yao, Ling Xu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mengxuan Wang *Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, People's Republic of China.
Zhenhong Xia *Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, People's Republic of China.
Wenyan NieShandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, People's Republic of China.
Chunlong WangShandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, People's Republic of China.
Haoran NieShandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, People's Republic of China.
Shuai ZhangShandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, People's Republic of China.
Jiaqi QiuShandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, People's Republic of China.
Yang YangShandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, People's Republic of China.
Cuifang YaoShandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, People's Republic of China.
Ling XuDepartment of Respiratory Critical Care Medicine, Binzhou Medical University Hospital, Yantai, Shandong, People's Republic of China.
Baijiao AnShandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, Shandong, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The 797S mutation in EGFR disrupts the covalent binding of third-generation inhibitors, causing drug resistance. Currently, no clinically drug fully overcomes this resistance. Methods: We designed and synthesised a novel EGFR C797S-targeted inhibitor- Results: It was found that there were 10 new small-molecule inhibitors and compound Conclusion: We concluded that cyclopropylsulfonamide

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungCyclopropanesDrug DesignLung NeoplasmsProtein Kinase InhibitorsSulfonamidesAnimalsApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorErbB ReceptorsHumansMiceAntineoplastic AgentsCyclopropanesEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsSulfonamidesbiological activityEGFR C797S mutationEGFR-TKIsNSCLC

Identifiers

PMID40034406
PMCPMC11874779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.